Navigation Links
Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing

MILFORD, Mass. and DUBLIN, May 6 /PRNewswire/ -- Waters Corporation (NYSE : WAT) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT) announced today a collaboration that will create the world's first database for glycan analysis by UltraPerformance Liquid Chromatography® (UPLC®). Expected to be available in 2011, NIBRT will develop, maintain and license the database while Waters and NIBRT will co-market it worldwide.

Manufacturing biomolecules can be notoriously difficult. Correct glycosylation is essential if a protein is to achieve and maintain its correct structure and therapeutic efficacy. Protein glycosylation is strongly influenced by many environmental factors during cell culture, such as dissolved oxygen, pH, carbon source, and temperature. Any change in any of these conditions at any point in the process can put product integrity at risk. So consistent glycosylation is a sensitive marker of a well-controlled process.

Given the number of possible glycan structures that can attach to a protein, it can be extremely difficult and time-consuming for life science laboratories to identify and quantify them all.

The new database, to be developed by Professor Pauline Rudd's group in NIBRT, will be a first-of-its-kind repository of chromatographic retention times for sets of glycan structures associated with a range of biotherapeutics. The aim is to give biopharmaceutical manufacturers a timely and powerful tool for confirming the structure of various glycosylated proteins. Armed with more rapid and accurate information about glycosylation during the various stages of the manufacturing process, biopharmaceutical manufacturers can potentially gain a greater degree of control over their manufacturing process in line with regulatory guidelines aimed at guaranteeing safe and efficacious biotherapeutics.

"By combining our know-how in separations and glycan analysis with NIBRT's expertise in glycobiology we can make fast and accurate glycosylation analysis a reality for the makers of biotherapeutics," said Dr. Jeff Mazzeo, Director, Biopharmaceutical Business Operations, Waters Division. "Our goal is to simplify and introduce more certainty into the process of analyzing glycans and making quality biomolecules."  

"NIBRT's expertise in glycobiology together with Water's expertise in separation science will ensure that this collaboration will develop and deliver rapid and robust technologies for the assessment of glycoproteins, while meeting the requirements and guidelines of the regulatory agencies," said Dr. Maurice Treacy, NIBRT CEO.

Many protein-based biopharmaceuticals are glycosylated proteins. Glycosylation is a form of co-translational and post-translational modification that links glycans to proteins, lipids, and other organic molecules.  The glycans directly affect the efficacy and safety of glycoprotein biopharmaceuticals.

Recent advances in chromatographic approaches are leading to better resolution, sensitivity, and speed for greater reliability during the qualitative and quantitative analysis of protein glycosylation. UPLC is a proven approach for analyzing biomolecules and the glycan structures attached to them and for determining the relative proportions of each glycan structure.  

The Waters® UPLC Glycan Analysis Solution features an ACQUITY UPLC® BEH Glycan Separation Technology column and an ACQUITY UPLC System with fluorescence detection (FLR) to separate the released glycans of biopharmaceuticals as their 2-aminobenzamide (2-AB) derivatives. The UPLC Glycan Separation Solution provides robust, high-resolving, reproducible, and rapid methods that outperform analyses by HPLC.

When available, the combination of NIBRT's database together with the Waters UPLC Glycan Solution will readily assign glycan structures - complex, neutral, high-mannose, and sialylated - to each UPLC peak for confirming known structures present in a sample or to look at Gu values and identify unknown or unexpected glycans.

In an application note discussing its UPLC Glycan Analysis Solution, Waters describes its methodology for glycan analysis by UPLC in greater detail.

About Waters Corporation (

For over 50 years, Waters Corporation (NYSE: WAT) creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.5 billion in 2009 and 5,200 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

About NIBRT (

NIBRT - National Institute for Bioprocessing Research and Training, Dublin, Ireland is a centre of excellence that supports the biopharma sector by offering research platform solutions for bio-manufacturing and provides tailored accredited industrial training and academic educational programmes to students in purpose-built flexible and modern bioprocessing facilities that will facilitate the expansion of the bio-pharma sector in Ireland. For further information please refer to

Waters, UltraPerformance LC, UPLC, ACQUITY UPLC, and ACQUITY are trademarks of Waters Corporation.

SOURCE Waters Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard
2. New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
3. Volcano Corporation Presentation at Bank of America Merrill Lynch Health Care Conference to Be Webcast
4. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
5. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
6. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
7. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
8. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
9. Providence Service Corporation Releases Fourth Quarter and Year End 2009 Results
10. CVS Caremark Corporation Announces Quarterly Dividend
11. ASPEX Corporation is Shifting the Identity of SEMs
Post Your Comments:
(Date:11/30/2015)... Medical Systems (NYSE: VAR ) has signed a Memorandum of ... the largest hospital chain in India , to ... country. The MoU was signed by Dr. K. Prabakar , ... Varian,s India managing director, in ... intends to deploy its Access to Care program by leveraging the ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . --> ... Pharmaboardroom releases its new 98-page Mexico Healthcare and Life Sciences ... country of over 122 million people. --> Latin ... --> It offers companies, investors, policymakers, and stakeholders with an ... largest pharma and healthcare market in Latin America ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... by UPMC and KingMed Diagnostics researchers. Their review of ... that consultation with UPMC pathologists resulted in significantly altered treatment plans for more ...
(Date:11/30/2015)... ... 30, 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and ... to coincide with World AIDS Day. The multi-media project will be in audio documentary ... as he was dying of the disease. , A collaborative effort led by author, ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i ... years, announced today that Michigan-based Family Health Center (FHC) has selected i2iTracks as ... years, FHC was awarded the largest Affordable Care Act grant for Federally Qualified ...
Breaking Medicine News(10 mins):